Among the 18 tumours with pathogenic KRAS mutations, KRASG12 substitutions were most frequent (n = 14, 78%) and included 6 KRASG12D, 5 KRASG12V, 2 KRASG12S and 1 KRASG12C substitutions. This evidence concerns the gene KRAS and neoplasm.